NHF’s QMS is ISO 9001:2015 Certified

Government of Jamaica

NHF ADDS MORE DRUGS TO ITS INDIVIDUAL BENEFITS DRUG LIST

NHF ADDS MORE DRUGS TO ITS INDIVIDUAL BENEFITS DRUG LIST

Seven new drugs for the treatment of diabetes, ischaemic heart disease, hypertension, high cholesterol, asthma, epilepsy, major depression and vascular conditions have been added to the National Health Fund (NHF) Individual Benefits Drug List. These drugs cover the active ingredients Ezetimibe, Repaglinide, Clopidogrel, Montelukast, Divalproex Sodium and two combined preparations – Diosmin & Hesperidin and Atenolol & Chlorthalidone

The subsidies being offered by the NHF cover 30-50% of the cost of the drugs. The NHF has improved the subsidy for Sodium Valproate syrup used in the treatment of epilepsy. The subsidy for this drug that is available as Epilim Syrup 200mg has been increased from $345.60 to $580.61.

A new strength injection was also added for Leuprolide, a drug used in the treatment of prostate cancer. The 11.25 mg injection brings the total number of injections of various strengths to five injections available for prostate cancer beneficiaries.

The NHF Individual Benefits Drug List is continuously updated by the Medical Review Committee resulting in frequent additions to NHF Individual Benefits Drug list. Mrs. Ann Logan Individual Benefits Manager says these additions are efficacious drugs being prescribed by medical practitioners for their patients in the treatment of their chronic diseases. The expansion of the drug list enables more patients to access NHF benefits which will lead to a reduction in their out of pocket expenses.

New drug presentations as well as new drug labels for existing active ingredients were also added for other conditions covered by the NHF.

Contact: Rosemarie Lee

Public Information Officer, 906-1106

National Health Fund © 2024. All Rights Reserved.